MedTrace Logo

Intestinal Microbiome and Chemotherapy

NCT02875249 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2016-08-29

No results posted yet for this study

Summary

Chemotherapy is commonly used as myeloablative conditioning treatment to prepare patients for haematopoietic stem cell transplantation (HSCT). Chemotherapy leads to several side effects, with gastrointestinal (GI) mucositis being one of the most frequent. Current models of GI mucositis pathophysiology are generally silent on the role of the intestinal microbiome.

The aim of the study is to identify functional mechanisms by which the intestinal microbiome may play a key role in the pathophysiology of GI mucositis, the investigators applied high throughput DNA-sequencing analysis to identify microbes and microbial functions that are modulated following chemotherapy.

Conditions

Interventions

OTHER

patients stool collection

patients stool collection

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Emmanuel Montassier, PH · Nantes Univetsity Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02875249 on ClinicalTrials.gov